Acclaim for a precision oncology pioneer in Oregon

Like few other drugs in the history of oncology, Gleevec transformed the outlook for patients: a disease with a life expectancy of less than five years – chronic myeloid leukemia – became a...

Oregon’s colonoscopy trailblazer steps into new leadership role

Colorectal screening, primarily by colonoscopy, contributed to a steep drop in cancer incidence (Yang et al. 2014). David Lieberman, M.D., professor and head of gastroenterology and hepatology in...

Shining a light on cancer care disparities

Image: NCI. . For some marginalized populations in the U.S., barriers preventing access to radiation therapy and other lifesaving cancer care are as insurmountable as those in the poorest nations,...

Halting resurgent prostate cancers before they spread

Q&A: Prostate cancer expert Julie Graff, M.D., explains how a new treatment option fills a void for men with resurgent tumors. When prostate cancer isn't cured by surgery or radiation, the...

Cracking the code of advanced prostate cancer

Understanding the tumor-specific alterations that are most important for prostate cancer aggressiveness and treatment decision-making will be the focus of a Marquam Hill...

A new line of attack on deadly prostate cancers

Researchers have uncovered a potential drug target for stopping castration-resistant prostate tumors – the second leading cause of cancer death in the U.S. For decades, drug development for...

Exercise as medicine for cancer: Q&A with Kerri Winters-Stone

Cancer patients don’t need to avoid physical exertion, including exercise – contrary to once widely held belief. Exercise is not only safe during and after cancer treatment, studies have found...